Ocumension Therapeutics Announces 2023 Interim Results
Expanded Hospital NetworkHealthy Sales of the Company's Core Products1H 2023's Operating Revenue Surged 90% to RMB104 million HONG KONG, Aug 24, 2023 - (ACN Newswire) - Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its interim results for the six months ended 30 June 2023 ("the Period") today. During the Period, the market of ophthalmic drugs has significantly recovered from COVID-19. The Company has seized such an opportunity and made gre...